BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-282@pharmaconomics
DTSTAMP:20260707T034206Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:DNLI Phase 1 — TAK-594/DNL593 (estimated date)
DESCRIPTION:Phase 1 trial results for TAK-594/DNL593 in GRN-related frontotemporal dementia are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000020/ex991pressreleaseq42025.htm\n\nTrack it: https://www.pharmaconomics.com/e/282
URL:https://www.pharmaconomics.com/e/282
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DNLI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR